Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled QBW276 in Cystic Fibrosis
NCT02566044Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2017
- Primary completion
- Apr 2018
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of QBW276 in cystic fibrosis (CF), sponsored by Novartis. Started Sep 2017; status: completed.
02
Drugs
QBW276
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02566044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566044.